Myeloid leukemia associated with Down syndrome (ML-DS)īlastic plasmacytic dendritic cell neoplasia Transient abnormal myelopoiesis (syn.: transient myeloproliferative disorder) 223 Myeloid sarcoma (syn.: extramedullary myeloid tumor granulocytic sarcoma chloroma)Ģ%-4%, leukemia cutis (infants), chloromaįavorable in case of favorable karyotypes Provisional entity: AML with mutated CEBPA 212ĪML with myelodysplasia-related changes 220, 221Īcute myeloid leukemia, not otherwise specified (NOS) 213, 222 27 Provisional entity: AML with mutated NPM1 33, 212, 213ĥ%-10% (14%-22% in CN), type A mutation dominant, increasing by age The general management of pediatric AML, the management of specific pediatric AML cohorts (such as infants) or subtypes of the disease occurring in children (such as Down syndrome related AML), as well as new therapeutic approaches, and the role of supportive care are discussed.ĪML with recurrent genetic abnormalities 14, 15, 209–211ĪML with inv(3)(q21q26.2) or t(3 3)(q21 q26.2)/ RPN1-EVI1ĪML (megakaryoblastic) with t(1 22)(p13 q13)/ RBM15-MKL1 The particular relevance of new diagnostic and prognostic molecular markers in pediatric AML is presented. This paper aims to discuss differences between childhood and adult AML, and to highlight recommendations that are specific to children. The primary goal of an international expert panel of the International BFM Study Group AML Committee was to set standards for the management, diagnosis, response assessment, and treatment in childhood AML. State-of-the-art recommendations in adult AML have recently been published in this journal by Döhner et al.
![nonmem ebv nonmem ebv](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20180207074019663-0674:9781107707016:fig13_8.png)
Despite major improvements in outcome over the past decades, acute myeloid leukemia (AML) remains a life-threatening malignancy in children, with current survival rates of ∼ 70%.